Company intelligence / Profile preview
Synakis
Toronto, Ontario, Canadasynakis.ca ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Synakis is a Toronto-based pre-clinical biotechnology company developing biomaterial-based ocular therapies to preserve and restore vision. Its lead program, SNK-125, is a biodegradable, injectable, transparent hydrogel vitreous substitute intended to improve recovery after retinal detachment surgery. The company’s broader platform is aimed at serious eye diseases including glaucoma and retinal degenerative disorders such as age-related macular degeneration. Synakis originated from research associated with the University of Toronto and is advancing its technology through preclinical development supported by recent seed financing and Ontario innovation funding.
- Therapeutic areas
- Ophthalmology
- Modalities
- Hydrogel-based drug delivery therapyBiologicBiomaterial
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
University of TorontoOntario Centre of InnovationToronto Innovation Acceleration PartnersChiefswood Private CapitalGlycoNet
Beyond the preview
Go deeper on Synakis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Synakis.